Navigation Links
Stop & Shop Issues a Voluntary Recall of Stop & Shop Brand Sundae Cones

QUINCY, Mass., Jan. 29 /PRNewswire/ -- Following notification from its manufacturer, The Stop & Shop Supermarket Company has recalled its Stop & Shop brand [ice cream] Sundae Cones. The item was removed from store shelves because ingredients in the product were from Peanut Corporation of America (PCA) and has the potential to be contaminated with salmonella bacteria. The product has a UPC # 68826706258 and contains 8-4oz. cones in each package.

Customers who have purchased the product should discard any unused portions or bring their purchase receipt to any Stop & Shop for a full refund. To date, Stop & Shop has received no reports of illnesses associated with consumption of this product.

Stop & Shop is committed to the highest standards of food safety. Customers looking for additional information may call Stop & Shop's corporate brands hotline at 1-877-846-9949, M-F, 9am-5pm.

Customers looking for more information on peanut product recalls relating to the recent salmonella outbreak can go to the FDA's website

About Stop & Shop

The Stop & Shop Supermarket Company, based in Quincy, Massachusetts, employs more than 59,000 associates and operates stores throughout Massachusetts, Connecticut, Rhode Island, Maine, New Hampshire, New York and New Jersey.

SOURCE The Stop & Shop Supermarket Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Capital Blue Cross Issues Statement on Withdrawal of Merger
2. National Tour Begins to Promote Book and Discuss Key Issues Impacting the U.S. Workforce...and How the Obama Administration Can Prevent the Next Economic Catastrophe
3. FDA Issues Final Regulations for Genetically Engineered Animals
4. Beacon Equity Issues Technical Trade Alerts on Headline Stocks: LLY, PCS, CAG, FRX, TGT, DOW
5. New Research From EBRI: Study Examines Issues in Capping Tax Exclusion of Health Coverage
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
7. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
8. National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future
9. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited
11. Crucial OTC Marketing Issues to be Addressed by New OTC Perspectives Division of DTC Perspectives, Inc.
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: